Business context and reporting period
Issuer discrepancy: The supplied filing is Sigma Labs, Inc.’s Form 10-Q for the quarter ended September 30, 2012—not a filing identified as Nexttrip, Inc. Verify the issuer before relying on this summary. Sigma Labs develops manufacturing and materials technologies, including IPQA, and also earns consulting revenue. Its financial statements include B6 Sigma, Sumner, and La Mancha.
Financial performance and liquidity
| Metric | Three months ended Sept. 30, 2012 | Nine months ended Sept. 30, 2012 |
|---|---|---|
| Revenue | $456,369 | $650,094 |
| Gross profit / margin | $190,423 / 41.7% | $209,587 / 32.2% |
| Net loss | $15,107 | $649,755 |
| Operating cash flow | Not separately presented | $(327,230) |
Third-quarter revenue rose 23.5% year over year, while nine-month revenue fell 3.0%. Gross margin declined from 94.0% to 41.7% for the quarter and from 74.1% to 32.2% for the nine-month period. The filing attributes revenue primarily to consulting services; it reports no technology sales. Basic and diluted loss per share rounded to $(0.00).
At September 30, cash was $326,225, current assets were $508,076, current liabilities were $179,280, and working capital was $328,796. Total liabilities were $179,280, consisting of accounts payable and accrued expenses; no borrowings are reported. Cash fell by $326,888 from year-end 2011. Nine-month operating cash use increased from $290,038 in the prior-year period; investing cash flow was zero and financing cash flow was $342. Total assets were $756,361, versus $1,276,196 at December 31, 2011.
Changes, outlook, and risks
- Third-quarter net loss narrowed from $36,789; nine-month net loss improved slightly from $661,271. Payroll expense declined, which management attributed principally to executive salary reductions. Nine-month general and administrative expense also decreased.
- The 2011 nine-month comparative loss was restated from $964,271 to $661,271 because stock compensation expense had been overstated by $303,000. The filing reports no change to the comparative balance sheet or third-quarter loss from this restatement.
- Management expected IPQA commercialization in the first half of 2013 and continued development of other technologies for commercialization during fiscal 2013. These are expectations, not assured outcomes.
- As of November 9, 2012, management expected up to $400,000 of fourth-quarter revenue from three active B6 Sigma consulting contracts and up to $61,000 from seven Sumner contracts; La Mancha had none. Fixed-fee contracts carry cost-estimation and performance risks.
- The company disclosed substantial doubt about its ability to continue as a going concern: it has incurred losses and depends on expanding income opportunities. Management expected consulting revenue and available funds to cover expenses for the balance of 2012, but acknowledged no assurance of additional capital or profitable operations. There were no committed third-party funding sources or credit facilities.
- Management reported disclosure controls effective at a reasonable-assurance level and no material quarterly change in internal control over financial reporting. A director resigned effective November 9, 2012, without a stated disagreement; he planned to provide consulting services.
Important facts for investors to verify
- Confirm that Sigma Labs—not Nexttrip—is the intended issuer and that the filing period matches the intended analysis.
- Review the restatement and stock-based compensation accounting, including the unvested-share cancellations and expense recognition.
- Assess cash runway, consulting contract execution and margins, and the company’s ability to obtain financing.
- Track progress toward technology commercialization and distinguish management targets from contracted or realized revenue.
- Examine the going-concern disclosure and the risks of fixed-fee contracts and continued operating losses.